Bob Löwenberg

发表

The effect of oligonucleotide microarray data pre-processing on the analysis of patient-cohort studies

Marcel J. T. Reinders, Dick de Ridder, Frank J. T. Staal, 2006, BMC Bioinformatics.

HeatMapper: powerful combined visualization of gene expression profile correlations, genotypes, phenotypes and sample characteristics

Peter J. van der Spek, Sebastiaan Horsman, Roel G. W. Verhaak, 2006, BMC Bioinformatics.

Sequential gain of mutations in severe congenital neutropenia progressing to acute myeloid leukemia.

Bob Löwenberg, Jurgen R Haanstra, Mathijs A Sanders, 2012, Blood.

Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia.

Augustin Ferrant, Bob Löwenberg, Alois Gratwohl, 2003, The New England journal of medicine.

On the road to new drugs in acute myeloid leukemia.

Bob Löwenberg, B. Löwenberg, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.

Bob Löwenberg, Carlos Graux, Nancy Boeckx, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Acute myeloid leukemia and acute promyelocytic leukemia.

Bob Löwenberg, J. Griffin, M. Tallman, 2003, Hematology. American Society of Hematology. Education Program.

Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance.

Bob Löwenberg, André G Uitterlinden, Maarten A. Bijl, 2005, Blood.

Cytarabine dose for acute myeloid leukemia.

Augustin Ferrant, Bob Löwenberg, Alois Gratwohl, 2011, The New England journal of medicine.

Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML.

Bob Löwenberg, Daniel G Tenen, Ruud Delwel, 2003, The hematology journal : the official journal of the European Haematology Association.

Two splice-factor mutant leukemia subgroups uncovered at the boundaries of MDS and AML using combined gene expression and DNA-methylation profiling.

Marcel J T Reinders, Erdogan Taskesen, Yvette van Norden, 2014, Blood.

Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity.

Erdogan Taskesen, Bob Löwenberg, Bas J. Wouters, 2011, Blood.

Significance of murine retroviral mutagenesis for identification of disease genes in human acute myeloid leukemia.

Bob Löwenberg, Ruud Delwel, R. Verhaak, 2006, Cancer research.

DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia.

Fabien Campagne, Lucy Skrabanek, Bob Löwenberg, 2010, Cancer cell.

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

Bob Löwenberg, Benjamin L Ebert, Pierre Fenaux, 2017, Blood.

A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1)

Filippo Castiglione, Fabrizio Stracci, Torsten Haferlach, 2008, Haematologica.

A 17-gene stemness score for rapid determination of risk in acute leukaemia

Claude Preudhomme, Peter W. Zandstra, Bob Löwenberg, 2016, Nature.

Review Articles (434 articles)

Bob Löwenberg, Pierre Fenaux, Hartmut Döhner, 2008 .

A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia.

Bob Löwenberg, Jason Gotlib, Yixin Wang, 2007, Blood.

Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1.

Pu Zhang, Bob Löwenberg, Bas J. Wouters, 2007, Blood.

Sustainability and affordability of cancer drugs: a novel pricing model

Bob Löwenberg, B. Löwenberg, C. U. Uyl‐de Groot, 2018, Nature Reviews Clinical Oncology.

Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine.

Bob Löwenberg, Jakob Passweg, Carlos Graux, 2012, Blood.

Identification of a novel CBFB-MYH11 transcript: implications for RT-PCR diagnosis.

Bob Löwenberg, J. Gabert, J. Jansen, 2001, The hematology journal : the official journal of the European Haematology Association.

Identification of Molecular Predictors of Response in a Study of Tipifarnib Treatment in Relapsed and Refractory Acute Myelogenous Leukemia

David C. Atkins, Bob Löwenberg, David Atkins, 2007, Clinical Cancer Research.

Criteria for defining a complete remission in acute myeloid leukaemia revisited. An analysis of patients treated in HOVON‐SAKK co‐operative group studies

Bob Löwenberg, Matthias Theobald, E. Vellenga, 2005, British journal of haematology.

Hierarchical Bayesian formulations for selecting variables in regression models

Veronika Rockova, Emmanuel Lesaffre, Bob Löwenberg, 2012, Statistics in medicine.

FLT3 inhibition as a targeted therapy for acute myeloid leukemia

Bob Löwenberg, F. Lo‐Coco, M. Sanz, 2009, Current opinion in oncology.

Prognostic index for adult patients with acute myeloid leukemia in first relapse.

Bob Löwenberg, E. Vellenga, G. Ossenkoppele, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value

Bob Löwenberg, Mathijs A Sanders, M. Sanders, 2012, Haematologica.

Large-scale identification of novel potential disease loci in mouse leukemia applying an improved strategy for cloning common virus integration sites

Bob Löwenberg, Ruud Delwel, B. Löwenberg, 2002, Oncogene.

Genome-wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T-lymphoid features.

Lucy Skrabanek, Bob Löwenberg, Bas J. Wouters, 2009, Blood.

High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients.

Bob Löwenberg, Ruud Delwel, P. Sonneveld, 2003, Blood.

Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia.

Veronika Rockova, Bob Löwenberg, Ruud Delwel, 2012, Blood.

Resistance Prediction in AML: Analysis of 4,601 Patients from MRC/NCRI, HOVON/SAKK, SWOG, and MD Anderson Cancer Center

Bob Löwenberg, Elihu H. Estey, Megan Othus, 2014, Leukemia.

Molecular Minimal Residual Disease in Acute Myeloid Leukemia

Markus G. Manz, Bob Löwenberg, Carlos Graux, 2018, The New England journal of medicine.

Risk stratification of intermediate-risk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and gene expression markers.

Veronika Rockova, Bob Löwenberg, Bas J. Wouters, 2011, Blood.

SNPExpress: integrated visualization of genome-wide genotypes, copy numbers and gene expression levels

Sebastiaan Horsman, Bob Löwenberg, Mathijs A Sanders, 2008, BMC Genomics.

MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia.

Bob Löwenberg, M. Jongen‐Lavrencic, S. Sun, 2008, Blood.